|
WO2021041889A1
|
|
Decorticating screw
|
|
WO2021041825A1
|
|
Sphingolipid-based selenium compounds, methods for their preparation, and pharmaceutical uses thereof, including as antitumor agents
|
|
WO2021007094A1
|
|
Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
|
|
WO2020264496A1
|
|
Motion-activated, closed-loop non-invasive vagus nerve stimulation for neurorehabilitation
|
|
WO2020264156A1
|
|
Asymmetric dimethylarginine (adma) as a marker for vascular pathologies
|
|
US2020397377A1
|
|
Needle electrode fixation device and associated methods
|
|
WO2020257405A1
|
|
Compositions and methods targeting the nucleotide free state of ras to block oncogenic signaling and transformation
|
|
WO2020247567A1
|
|
Kdm4b inhibitors for the treatment of inflammatory diseases and disorders
|
|
US2020372642A1
|
|
Positional biomarkers based on brain imaging
|
|
EP3744293A1
|
|
Expandable vertebral body replacement device
|
|
WO2020206208A1
|
|
Nerve holder device
|
|
WO2020142694A2
|
|
Ero1-alpha inhibitors
|
|
US2020206313A1
|
|
Polypeptide nanotubes linked by disulfide bonds for targeted delivery of cytotoxic therapies
|
|
WO2020092696A1
|
|
Ex vivo activation and expansion of t cells for adoptive cell transfer therapy
|
|
US2020109434A1
|
|
Compositions and Methods for Diagnosing Recurrent Focal and Segmental Glomerulosclerosis (rFSGS)
|
|
WO2020069439A1
|
|
Pharmaceutical combination for the treatment of cancer
|
|
CA3109216A1
|
|
Recombinant myxoma viruses and uses thereof
|
|
WO2020028222A1
|
|
Compounds for the treatment of neurological or mitochondrial diseases
|
|
AU2019276640A1
|
|
Glycan analysis of proteins and cells
|
|
WO2019222750A1
|
|
Noninvasive cranial nerve therapy
|
